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Abstract The mucopolysaccharidoses (MPSs) are inherited
lysosomal storage disorders caused by the absence of
functional enzymes that contribute to the degradation of
glycosaminoglycans (GAGs). The progressive systemic
deposition of GAGs results in multi-organ system dysfunction
that varies with the particular GAG deposited and the specific
enzyme mutation(s) present. Cardiac involvement has been
reported in all MPS syndromes and is a common and early
feature, particularly for those with MPS I, II, and VI. Cardiac
valve thickening, dysfunction (more severe for left-sided than
for right-sided valves), and hypertrophy are commonly
present; conduction abnormalities, coronary artery and other
vascular involvement may also occur. Cardiac disease emerges
silently and contributes significantly to early mortality.
The clinical examination of individuals with MPS is often
difficult due to physical and, sometimes, intellectual patient
limitations. The absence of precordial murmurs does not
exclude the presence of cardiac disease. Echocardiography
and electrocardiography are key diagnostic techniques for
evaluation of valves, ventricular dimensions and function,
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technique for evaluation of coronary artery involvement
remains unsettled.
Standard medical and surgical techniques can be
modified for MPS patients, and systemic therapies such as
hematopoietic stem cell transplantation and enzyme re-
placement therapy (ERT) may alter overall disease progres-
sion with regression of ventricular hypertrophy and
maintenance of ventricular function. Cardiac valve disease
is usually unresponsive or, at best, stabilized, although ERT
within the first few months of life may prevent valve
involvement, a fact that emphasizes the importance of early
diagnosis and treatment in MPS.
Characteristics and implications of mucopolysaccharidosis
The mucopolysaccharidoses (MPSs) are lysosomal storage
disorders, characterized by the functional deficiency caused
by genetic mutation of one of the particular lysosomal
enzymes which act in the sequential catabolism of
glycosaminoglycans (GAGs, formerly known as mucopo-
lysaccharides) (Wraith 1995). Individuals with one of these
rare metabolic disorders are affected by progressive
accumulation of incompletely degraded GAGs within
virtually all organ systems, although distribution varies
depending on the specific disease (Wraith 1995). The
characteristics of the currently recognized MPS disorders
and their subtypes are summarized in Table 1.
Accumulation of partially-degraded GAGs progressively
affects multiple organ systems and, possibly together
with a cascade of secondary events, produces the classic
phenotypes seen in these disorders. Typical manifestations
include dwarfism (i.e. growth retardation), skeletal and joint
deformities (e.g. dysostosis multiplex, including ‘claw’
hands), dysmorphic facial characteristics, central nervous
system involvement (including mental retardation depending
on type and severity, spinal cord compression and increased
intracranial pressure), ocular (corneal clouding, retinal
degeneration and blindness) and hearing impairment,
respiratory difficulties, gastrointestinal pathology (e.g.
hepatosplenomegaly, bowel dysfunction) and umbilical or
inguinal hernias (Ferrari et al. 2011;G a r c i ae ta l .2010;
Lachman et al. 2010; Wraith 1995). The cardiovascular
system is very commonly affected. While cardiac disease has
been found in all of the MPS disorders, most studies indicate
Table 1 Characteristics of all known MPS types with respect to demographics, patients’specifics and genetic/biochemical profile (Compiled from
(Neufeld and Muenzer 2001) and (V alayannopoulos et al. 2010))
MPS type (eponym) Incidence per
10
5 live births;
inheritance
pattern
Typical age
at diagnosis
Typical life expectancy
if untreated
Enzyme deficiency GAG
MPS I Hurler (H)
MPS I Hurler-
Scheie (H-S)
MPS I Scheie (S)
0.11-1.67; AR H: < 1 year
H-S: 3–8 years S:
10–20 years
H: death in childhood
H-S: death in teens or early
adulthood S: normal to
slightly reduced lifespan
α-L-iduronidase DS, HS
MPS II (Hunter) 0.1-1.07; XR 1-2 years
when rapidly
progressing
rapidly progressing:
death<15 years
slowly progressing: death in
adulthood
iduronate-2-sulfatase DS, HS
MPS III
(Sanfilippo)
A-B-C-D
0.39-1.89; AR 4-6 years death in puberty or early
adulthood
heparan sulfamidase (A)
N-acetyl-α-D-glucosaminidase (B)
acetyl-CoA-α-glucosaminidase
N-acetyltransferase (C)
N-acetylglucosamine-6-sulfatase (D)
HS
MPS IV (Morquio)
A-B
0.15-0.47; AR 1-3 years death in childhood-
middle age
N-acetylgalactosamine-6-sulfatase (A)
β-galactosidase (B)
CS, KS (A)
KS (B)
MPS VI
(Maroteaux-
Lamy)
0-0.38; AR rapidly progressing:
1–9 years
slowly progressing:
> 5 years
rapidly progressing: death
in 2nd-3rd decade
slowly progressing: death in
4-5
th decade
N-acetylgalactosamine-4-sulfatase DS
MPS VII (Sly) 0-0.29; AR neonatal to
adulthood
death in infancy-
4th decade**
β-D-glucuronidase CS, DS, HS
MPS IX
(Natowicz)*
unknown adolescence unknown hyaluronidase CS
AR: autosomal recessive; CS: chondroitin sulfate; DS: dermatan sulfate; GAG: glycosaminoglycan; H: Hurler syndrome; HS: heparan sulfate; H-S:
Hurler-Scheie syndrome; KS: keratan sulfate; S: Scheie syndrome; XR: X-linked recessive
*only 1 patient reported in literature (Natowicz et al. 1996); **death can occur in utero with hydrops fetalis
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(Chen et al. 2005; Dangel 1998; Fesslová et al. 2009;G r o s s
et al. 1988;L e a le ta l .2010; Mohan et al. 2002; Wippermann
etal.1995)t h a ni nM P SI I Io rI V , while the frequency in MPS
VII is difficult to judge due to the small number of patients.
Clinical findings and severity depend on the particular
MPS syndrome, the specific genetic mutations involved
(Karageorgos et al. 2007; Matte et al. 2003; Yogalingam et
al. 2004) and, to some extent, on the individual patient’s
biology with other, still undefined factors that lead to
variability in phenotype within MPS syndromes. Based on
severity and age at onset, some of the MPS syndromes have
been categorized into slowly- and rapidly-progressing
phenotypic subtypes (Jones et al. 2009; Muenzer et al.
2009b; Neufeld and Muenzer 2001; Schwartz et al. 2007;
Swiedler et al. 2005; Thomas et al. 2010). Phenotypic
heterogeneity is seen in all types of MPS (Martins et al.
2009; Muenzer et al. 2009b; Neufeld and Muenzer 2001).
The rapidly progressing form of MPS I (i.e. Hurler
syndrome) is associated with central nervous system
involvement and early-onset cardiac disease (Brosius and
Roberts 1981; Neufeld and Muenzer 2001). Phenotypic
severity, including mortality, in MPS II has been based, thus
far, on the degree of developmental delay and GAG
excretion (Jones et al. 2009; Schwartz et al. 2007). While
central nervous system involvement does not play a role in
MPS VI, phenotypic severity in somatic growth and
pulmonary function has been correlated with urinary GAG
excretion (Swiedler et al. 2005).
Regardless of phenotype, all forms of MPS are associated
with morbidity and early mortality (Table 1)( B r o s i u sa n d
Roberts 1981; Giugliani et al. 2007; Jones et al. 2009;
Martins et al. 2009). Premature death in untreated MPS
syndromes is most commonly a result of respiratory
compromise and cardiac disease (Chen et al. 2005;G r o s s
et al. 1988; Jones et al. 2009; Krovetz et al. 1965). Reported
cardiac causes of death include heart failure, sudden death
from arrhythmias (including complete atrioventricular block)
(Hishitani et al. 2000; Martins et al. 2009) and coronary
occlusion (Lin et al. 2005).
Cardiac disease associated with MPS
Early reports
Cardiac findings were not prominent in the earliest reports of
Hurler syndrome (Hurler 1919) and Hunter syndrome
(Hunter 1917). Beginning in the 1940-50s, detailed post-
mortem cardiac studies on individuals clinically diagnosed
with MPS (previously referred to as “gargoylism”)w e r e
reported by several investigators (Emanuel 1954;L i n d s a y
1950;S t r a u s s1948). These early morphologic studies
occurred well before the biochemical basis of MPS disorders
was established. It was only in 1965 that Victor McKusick,
trained as a cardiologist and the father of modern medical
genetics, established the classification of the MPS disorders
based upon patterns of mucopolysacchariduria, a system that
continues, with few changes, to be in use today (Kaplan
1969;M c K u s i c ke ta l .1965;M c K u s i c k1969). The first
MPS cardiac studies to include supporting biochemical data
are those of Krovetz et al. (Krovetz et al. 1965), Renteria et
al. (Renteria et al. 1976) and Brosius and Roberts (Brosius
and Roberts 1981).
Prevalence, severity and time of onset
Becauseoftherarityofthedisorders(Table1), cardiac studies
involving large numbers of individuals with a particular MPS
are uncommon. Nevertheless, the prevalence and severity of
cardiovascular disease in individuals with MPS (especially
MPS I, II and VI) is strikingly high, occurring in 60-100% of
those studied (Chen et al. 2005; Dangel 1998; Fesslová et al.
2009;L e a le ta l .2010; Martins et al. 2009; Pastores et al.
2007; Wippermann et al. 1995). Cardiac valve involvement
appears more common in those syndromes in which
dermatan sulfate catabolism is deranged (MPS I, II and VI
but not MPS III and IV) (Chen et al. 2005; Dangel 1998;
Fesslová et al. 2009;L e a le ta l .2010).
Within a particular type of MPS, cardiac pathology
generally develops earlier in life for individuals with more
rapidly progressing types of MPS (e.g. Hurler syndrome)
(Brosius and Roberts 1981; Hirth et al. 2007)a n dm a yb e
d e l a y e di ns l o w l yp r o g r e s s i n gf o r m s( e . g .H u r l e r - S c h e i ea n d
Scheie syndromes) (Soliman et al. 2007). Nonetheless,
cardiac disease is a uniformly progressive process (Chen et
al. 2005;D a n g e l1998; Fesslová et al. 2009; Giugliani et al.
2007; Krovetz et al. 1965; Leal et al. 2010; Mohan et al.
2002; Muenzer et al. 2009b) with both incidence and severity
increasing over time (Fesslová et al. 2009). Despite this,
clinical signs and symptoms of cardiac involvement are
uncommon leading to an underestimate of the true prevalence
of cardiac disease. For example, only six of 26 patients with
documented echocardiographic disease presented with
cardiovascular signs or symptoms (Dangel 1998;G r o s s
et al. 1988;L e a le ta l .2010), a finding which underscores
the importance of a complete cardiac evaluation after
establishing a diagnosis of MPS.
V alvular disease
Progressive cardiac valve pathology is the most prominent
and uniform cardiac manifestation (60-90%) of patients
with MPS (Fesslová et al. 2009; Wippermann et al. 1995).
Cardiac valve thickening with associated dysfunction has
been reported in more than 80% of patients with MPS I
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2007; Thomas et al. 2010), 57% of patients with MPS II
(Wraith et al. 2008) and in all individuals with MPS VI
except for the most slowly progressing ones (Azevedo et al.
2004; Brooks et al. 2005; Scarpa et al. 2009).
Most studies have reported that valvular regurgitation,
rather than stenosis, is more common and that the mitral
valve, rather than the aortic, is most commonly affected. In
general, left-sided valves (mitral & aortic) are more
severely affected than those on the right side of the heart
(tricuspid & pulmonary) (Dangel 1998; Fesslová et al.
2009;K r o v e t ze ta l .1965; Rigante and Segni 2002;
Thomas et al. 2010). The mitral valve leaflets are markedly
thickened and cartilage-like, with particularly thickened
edges (Fig. 1). The subvalvular apparatus of the mitral
valve develops shortened chordae tendineae and thick
papillary muscles resulting in dysmorphic and poorly
mobile leaflets (Fig. 1) (Tan et al. 1992; Y ano et al. 2009).
Calcific deposits commonly occur in the mitral annular
region (Johnson et al. 1981; Renteria et al. 1976). The
aortic valve presents a similar picture of progressive valve
thickening and dysfunction (Fig. 1).
These pathologic alterations result in regurgitation
(insufficiency) and/or stenosis, both of which are easily
identified by two-dimensional echocardiography and Doppler
examination (Johnson et al. 1981; Maganti et al. 2010)
(Fig. 2). V alvular stenosis or regurgitation may lead to left
atrial and/or left ventricular volume overload, left ventricular
dilatation, left ventricular hypertrophy (L VH), and ultimately
to systolic and diastolic dysfunction. In a retrospective case
series of children with various forms of MPS, LVH and
diastolic dysfunction emerged at an early stage, whereas left
ventricular dilation and systolic dysfunction occurred at older
ages and later disease stage (Leal et al. 2010)( F i g .3).
Coronary artery disease
Coronaryartery narrowingand/or occlusion has beendescribed
in individuals with all types of MPS (Braunlin et al. 1992;
Brosius and Roberts 1981; Danks et al. 1972;F a c t o re ta l .
1978; Kettles et al. 2002;K u r i h a r ae ta l .1996;R e n t e r i ae ta l .
1976; Shimamura et al. 1976; Tan et al. 1992), but is most
common in MPS I and MPS II. Diffuse intimal proliferation
from GAG deposition within large epicardial coronary arteries
can occur early, especially in rapidly progressing MPS I
(Brosius and Roberts 1981), causing high-grade narrowing
(Fig. 4). The lumens are nearly always central in location.
Occlusion within coronary arterioles (rather than in the large
epicardial coronary arteries) and a large left ventricular apical
aneurysm have been described in an individual with MPS VI
suggesting that different types of coronary involvement may
occur in the various MPS syndromes (Oudit et al. 2007). A
similar apical aneurysm has been reported in MPS II (Kettles
et al. 2002), although a description of the coronary arterioles
was not provided.
Other vascular changes
The great vessels in individuals with MPS may have
increased wall thickness and may either be narrowed
(Taylor et al. 1991; Wraith et al. 2008) or dilated (Hinek
and Wilson 2000). Diffuse narrowing of the thoracic and
abdominal aorta (Taylor et al. 1991) has been reported to
occur in 30% of a small series of individuals with MPS I
and II. Narrowing may occur at the aortic isthmus, a
location typical for coarctation (Braunlin et al. 2000), and
may require surgical intervention for relief of significant
obstruction. Although systemic hypertension due to arterial
narrowing is common among individuals with MPS I and II
(Taylor et al. 1991; Wraith et al. 2008), it has been less
Fig. 1 (a) Autopsy specimen from a female patient with Hurler
syndrome at the age of 2.8 years showing (a) a dysplastic and
thickened mitral valve (arrow) with a thickened subvalvular apparatus
and parietal left ventricular hypertrophy and (b) a dysplastic aortic
valve (arrow) (Fesslová et al. 2009) (copyright Fesslová et al. Cardiol
Young 2009)
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(Giugliani et al. 2007).
Dilation of the ascending aorta and markedly reduced
aortic elasticity has been reported in MPS I (Nemes et al.
2008). This could be attributed to the downstream effects of
GAGs on the assembly of tropo-elastin, resulting in elastin
that is both decreased in content and abnormal in structure
(Hinek and Wilson 2000). Studies in MPS I and MPS VII
animals have revealed that aortic dilation is likely due to
degradation of elastin by matrix metalloproteinase-12 and/or
cathepsin S (Ma et al. 2008; Metcalf et al. 2010). Aortic root
replacement has not been reported for MPS patients to date.
Conduction abnormalities
Conduction abnormalities and sinus tachycardia have been
reported in 44% of the patients with MPS VI and in 7% of a
subset of the Hunter Outcome Survey of MPS II patients,
respectively (Azevedo et al. 2004; Wraith et al. 2008).
Several case reports have documented the development of
Fig. 4 Epicardial right coronary artery from untreated 1-year-old male
with rapidly progressing MPS I. Note diffuse myointimal proliferation
(arrow). (Alcian blue stain)
Fig. 3 Echocardiographic evaluations in patients with MPS (2–
14 years old, mean age 9 years; MPS I-II-III-IV-VI-VII) indicate that
left valve lesions, left ventricular hypertrophy (LVH) and pulmonary
hypertension are the most common cardiac findings (Leal et al. 2010).
AR: aortic regurgitation; MR: mitral regurgitation; MS: mitral
stenosis; MR/MS: both lesions; *LVH: septal and posterior wall
hypertrophy of left ventricle
(a)
(b)
Fig. 2 Echocardiography and
Doppler interrogation of mitral
(a) and aortic (b) valve in a
50-year-old male with MPS VI
(a) Short-axis view of thickened
mitral valve (arrow) in diastole
(left). Colour Doppler
demonstration of mitral
regurgitation (right). (b) Short-
axis view demonstrating
thickened trileaflet aortic
valve (arrow) in systole (left).
Colour Doppler demonstrating
turbulent systolic flow of aortic
valve stenosis (right)
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subsequent need for cardiac pacing and sudden death
(Dilber et al. 2002; Hishitani et al. 2000; Misumi et al.
2010). Fibrosis of the conduction system with GAG
infiltration was seen in one individual with MPS VI who
died suddenly (Keller et al. 1987).
Underlying cardiac pathology
AlthoughthepathobiologyofMPSisincompletelyunderstood,
it is generally assumed that the influence of progressive GAG
infiltration and its downstream effects are responsible for
anatomical and functional alterations of the valves, coronary
arteries, great vessels, conduction system and myocardium
(Hinek and Wilson 2000; Martins et al. 2009).
Cardiac histopathology and electron microscopy are most
complete in MPS I. These characteristically show increased
GAG content as well as infiltration of ‘clear’ cells and
granular cells within cardiac valves (leaflets, annuli and
chordae tendineae), endocardium, myocardial walls, coronary
arteries, aorta (Renteria et al. 1976) and the conduction
system (Hishitani et al. 2000). Examination of heart tissue by
light microscopy shows the morphological consequences of
GAG storage, i.e. vacuolated cells with enlarged cytoplasm
(Fig. 5).
Role of GAGs in pathogenesis
The heparan-, dermatan-, chondroitin- and keratan-sulfated
GAGs are normal components of cardiac valves and the great
vessels (Grande-Allen et al. 2003; Gupta et al. 2009; Latif et
al. 2005). Recent studies have implicated alterations in
proteoglycan (GAG) metabolism in pathological processes
such as myxomatous mitral valves (Grande-Allen et al. 2003;
Rabkin et al. 2001), aortic aneurysm (Theocharis et al. 2003),
and atherosclerotic vasculature (Nakashima et al. 2008).
Dermatan-sulfated GAGs are a prominent component of
normal cardiac valve tissue (Latif et al. 2005)s oi ti sn o t
surprising to find a strong association between MPS I, II and
VI (that result in the accumulation of dermatan-sulfated
GAGs) and cardiac valve disease (Dangel 1998; Leal et al.
2010). Additionally, deep within the cardiac valves of all MPS
syndromes, lie GAG-laden cells that have variously been
called ‘clear’ cells, ‘Gargoyle’ cells or ‘Hurler’ cells. Recently,
these cells have been identified in MPS I as being activated
valvular interstitial cells engaged in attempted, but ineffective,
valve repair (Braunlin et al. 2010). The mechanisms by which
the accumulated heparan-sulfated proteoglycans and attendant
vascular interstitial cells affect the vasculature of the
great vessels and coronary arteries in MPS I, II, and III (the
heparan-sulfate accumulating MPS disorders) remains
unknown. One hypothesis for the role of GAGs in cardiac
disease could be that GAGs induce inflammation by
activating the Toll-like receptor 4 pathway, leading to
upregulation of degradative proteases (Simonaro 2010).
Diagnosis and regular monitoring of cardiac disease
in MPS
Physical examination
The physical examination not only of young children, but
also of adults with MPS is challenging due to both physical
and, sometimes, intellectual patient limitations. A complete
examination includes right upper as well as lower extremity
blood pressures (to exclude aortic obstruction), pulse rate,
palpation of pulses in all extremities, as well as careful
auscultation of the heart and lungs. Other aspects of a
complete cardiac examination, evaluating jugular venous
distention or hepatosplenomegaly, may be unrewarding due
to shortened necks and the presence of GAG-laden and
enlarged visceral organs. Dysostosis multiplex and joint
stiffening may complicate blood pressure measurements.
Auscultation is often suboptimal due to pronounced upper
airway noises. While the cardiac sounds are generally easily
heard, the absence of cardiac murmurs does not exclude the
presence of significant cardiac disease. Mild to moderate
degrees of valvular stenosis and/or regurgitation can be
present without significant murmurs.
Non-invasive techniques
Because of its versatility, ease of performance and cost-
effectiveness, transthoracic two-dimensional echocardiography
is the primary imaging modality used to evaluate cardiac
a n a t o m ya n df u n c t i o ni np a t i e n t sw i t hM P S( A g u i l a re ta l .
2008). Echocardiography provides reliable measurements of
Fig. 5 Light microscopy of the mitral valve of a girl with MPS VI at
14 years of age, demonstrating enlarged and foamy appearing fibroblasts
(arrows) (hematoxylin and eosin staining, magnification x 20)
1188 J Inherit Metab Dis (2011) 34:1183–1197ventricular chamber dimensions (both systolic and diastolic)
and left ventricular posterior and septal wall thicknesses,
which can be normalized for body surface area. Accurate
measures of ventricular function (shortening fraction &
ejection fraction) can be determined. Doppler interrogation
of cardiac valves allows accurate grading of valve stenosis
and regurgitation as well as estimation of cardiac output and
right ventricular/pulmonary artery pressures (Aguilar et al.
2008). Despite its benefits, echocardiography provides only
limited information in the assessment of coronary artery
anatomy and pathology. Transthoracic echocardiography can
usually be performed without sedation if the child is allowed
to remain in his parent’s arms or if he can be distracted by
videos or toys. In some instances, however, transthoracic
echocardiography may be suboptimal due to limited tolerance
for examination, abnormal cardiac position, scoliosis, or
hyper-aerated lung fields. Transesophageal echocardiography
is not routinely employed in those with MPS as it requires
monitored sedation or general anaesthesia, which may be
poorly tolerated because of the airway complications that are
not infrequent in this patient population.
Magnetic resonance imaging (MRI) and computed
tomography (CT) are advanced techniques not routinely
used for cardiac evaluation in children. Although MRI is a
reliable tomographic technique for assessing cardiac anatomy
and function (with quantification of volumetrics and
regurgitation), its application is limited by heart rate
constraints, slow acquisition times, and the need for
sedation, and may be contraindicated in individuals with
implanted devices (Aguilar et al. 2008). Cardiac CT
angiography, advantageous with respect to acquisition speed
and resolution, is limited by relatively large radiation
exposure and suboptimal assessment of valve morphology
and hemodynamics (Aguilar et al. 2008).
Evaluation for the presence of coronary arteriopathy in
the MPS disorders is problematic because the diffuse nature
of coronary involvement differs substantially from typical
atherosclerotic coronary disease. While the latter is believed
to be reliably excluded by a normal CT angiogram (Taylor
et al. 2010), this may not be true in MPS coronary disease.
Coronary angiography may be therefore indicated in those
suspected of having coronary artery pathology (Winchester
et al. 2010), but may miss significant disease due to the
diffuse nature of the process in MPS (Braunlin et al. 1992).
Intravascular ultrasound has successfully identified significant
coronary artery narrowing in adults with Fabry’sd i s e a s e
(Kovarnik et al. 2008), but has not been reported in the MPS
disorders and remains primarily a research tool. The value of
non-invasive dobutamine or adenosine stress testing combined
with echocardiography or MRI imaging is currently under
study in individuals with MPS.
Standard 12-lead electrocardiography (ECG) is the
second most important technique used to evaluate the hearts
of individuals with MPS. Assessment of heart rate and rhythm
as well the determination of conduction times (PR interval,
QRS duration, corrected QTinterval) are all important clues to
the health of the underlying conduction system. In instances
where symptoms suggestive of either conduction block or
arrhythmia are present, more prolonged monitoring (Holter or
event monitor) is required for identifying arrhythmias and heart
rate variability. Although rarely detected on routine ECG, one
should pay attention for signs of ischemia in this patient
population.
Recommendations
Individuals with MPS should undergo physical examination,
echocardiography and 12-lead ECG at the time of diagnosis,
followed by regular monitoring (every 1 to 2 years for MPS I
and VI, or 1 to 3 years for MPS II) thereafter in order to
provide appropriate diagnosis and management (Giugliani et
al. 2007; Muenzer et al. 2009a, b). Additional cardiac
evaluations should be considered before major operative
interventions. Complete evaluation includes right arm and
leg blood pressure measurements, careful auscultation,
performance of a full transthoracic two-dimensional and
Dopplerechocardiogram,12-leadECG,andHoltermonitoring
as indicated (Giugliani et al. 2007; Muenzer et al. 2009a, b).
Performance and interpretation of echocardiography should
be standardized (in terms of equipment and settings) and
provided by individuals familiar with expected pathological
findings in patients with MPS (Fig. 6).
Management of cardiac disease in MPS
Current patient management is dependent upon the type of
MPS present and may include standard pharmacological
and surgical care, enzyme replacement therapy (ERT) or
hematopoietic stem cell transplantation (HSCT). While
standard medical care has focused on medications for heart
failure and cardiac surgery (V alayannopoulos et al. 2010),
systemic therapies aim to restore functional enzyme and slow,
or possibly reverse, disease progression. Systemic therapies
have been shown to lengthen life (HSCT) and to improve
clinical status (HSCTand ERT), particularly when performed
earlyinlife(Martinsetal.2009; Muenzer et al. 2009a; Prasad
and Kurtzberg 2010b; V alayannopoulos et al. 2010).
Pharmacological and surgical approaches
Intheadultpopulation,standardpharmacologicalandsurgical
management has been driven by cardiac pathophysiology
regardless of MPS type. One longitudinal cohort study
reported 33% of 48 patients with MPS received standard drug
therapy for hemodynamic complications caused by valvular
J Inherit Metab Dis (2011) 34:1183–1197 1189lesions or heart failure (Fesslová et al. 2009). In the pediatric
population, due to the absence of large-scale, long-term
pharmacological studies, clear recommendations regarding
pharmacologic management have not been defined (O’Connor
et al. 2010). Afterload reduction with angiotensin-converting
enzyme inhibitors or angiotensin II receptor blockers has been
reported as useful in small series of non-MPS children
with aortic or mitral regurgitation, hypertension or heart
failure (O’Connor et al. 2010). Although these drugs are
frequently used, formal recommendations have yet to be
made regarding their use in children, either with or without
MPS (O’Connor et al. 2010).
Progressive deposition of GAGs within the cardiac valves
can lead to regurgitation or stenosis severe enough to require
surgical intervention. Cardiac valve surgery is among the
procedures frequently performed in patients with MPS (Arn et
al. 2009). Successful valve repair or replacement has been
reported in individuals with all types of MPS (Table 2). Mitral
valve replacement was performed in MPS I (Kitabayashi et
al. 2007; Kraiem et al. 2001), MPS II (Antoniou et al. 2009)
and MPS VI (Marwick et al 1992); a 6-year-old with MPS III
(Muenzer et al. 1993) has undergone mitral valvuloplasty.
Successful aortic valve replacement has been reported in
adults with slowly progressing MPS I (Masuda et al. 1993),
MPS IV (Barry et al. 2006; Nicolini et al. 2008; Pagel and
Almassi 2009) and MPS VI (Wilson et al. 1980). Due to
pathological abnormalities in the native pulmonary root, the
Ross procedure, where the aortic valve is replaced by the
patient’s own pulmonary valve, is contraindicated in individ-
uals with MPS (Barry et al. 2006). Combined aortic and
mitral valve replacement was successfully performed in
adults (Butman et al. 1989; Fischer et al. 1999; Minakata et
al. 1998) and in teens as young as 12 years of age (Goksel et
al. 2009) with MPS I and in adults with MPS II (Joly et al.
2004) and MPS VI (Hachida et al. 1996; Tan et al. 1992).
Fesslová et al. have reported favorable mitral and aortic valve
replacement in three patients with Scheie syndrome and one
with slowly progressing Hunter syndrome ranging in age
from 13–53 years (Fesslová et al. 2009). Other successful
cardiac procedures include coronary artery bypass surgery in
a 56-year-old male with slowly progressing MPS I (Minakata
et al. 1998), closure of an outlet type of ventricular septal
defect in a child with MPS III (Kourouklis et al. 2007), and
repair of ‘coarctation’ of the aorta after HSCT in a 3-year-old
boy with rapidly progressing MPS I (Braunlin et al. 2000).
While the long-term outcome is generally favorable
(Hachida et al. 1996; Marwick et al. 1992; Tan et al. 1992;
Wilson et al. 1980), candidacy for surgical intervention
must be based on general health status and potential risks
posed by intubation and post-operative care. Craniofacial
abnormalities, excessive oral pharyngeal and upper airway
tissue, a short stiff neck, and unstable atlantoaxial joint
(with risk of spinal cord injury) (Giugliani et al. 2007) may
combine to complicate intubation and airway management
in select patients (Walker et al. 1994). Intubation with use
of fiber-optic bronchoscope and expertise in dealing with
uncommon airway issues in this patient population is often
necessary. Endocarditis prophylaxis is currently recommen-
ded only in patients with a history of endocarditis, certain
residual postoperative lesions, or a prosthetic valve (Maganti et
al. 2010; Wilson et al. 2007).
Systemic therapies
HSCT has been successfully employed for metabolic
correction of MPS disorders for the past 30 years (Hobbs
et al. 1981; Krivit et al. 1984). While this therapeutic
approach has, in the rapidly progressing form of MPS I,
￿ Surface 12-lead: rhythm, conduction blocks, bundle
branch blocks
￿ Holter 24-hours: rhythm, heart rate (values and 
variability by time and frequency domain), 
supraventricular and ventricular arrhythmia
ECG
￿ 2D transthoracic 
￿ M mode
￿ Doppler
￿ Colour Doppler 
￿ Tissue Doppler 
ECHO
posterior wall thickness
interventricular septal thickness
left ventricular dimension
left ventricular mass/hypertrophy
left ventricular function 
valve thickness and function
Fig. 6 Recommended diagnostic
techniques and assessments to
evaluate cardiac anatomy
and function in patients with
MPS at initial diagnosis and at
regular intervals thereafter
(every 1 to 2 years for MPS I
andVI,or1to3yearsforMPSII)
2D: 2-dimensional; ECG:
electrocardiography; ECHO:
echocardiography
1190 J Inherit Metab Dis (2011) 34:1183–1197significantly increased long-term survival and arrested
neurologic deterioration (Orchard et al. 2007), its
beneficial effects in the remaining MPS disorders have
not been proven (Prasad and Kurtzberg 2010a, b).
Associated risks of HSCT are high (Boelens et al. 2009;
Prasad and Kurtzberg 2010a, b) and, as a consequence,
HSCT is considered standard of care for only the most
rapidly progressing forms of MPS I (Prasad and Kurtz-
berg 2010a, b).
Long-term metabolic correction by HSCT results in
preservation of cardiac function and regression of cardiac
hypertrophy (Braunlin et al. 2003; Gatzoulis et al. 1995;
Guffon et al. 2009; Krivit et al. 1984; Viñallonga et al.
1992). Cardiac valvular thickening is less likely to resolve
(Herskhovitz et al. 1999; Malm et al. 2008) and left-sided
valvular stenosis or regurgitation may remain unchanged
(Yamada et al. 1998) or progress (Braunlin et al. 2003).
Coronary artery narrowing and occlusion from myointimal
proliferation in rapidly progressing MPS I appears to be
arrested after successful HSCT (Braunlin et al. 2001), a
factor which may play a significant role in prolonged
survival in these patients (Orchard et al. 2007). The
progression of cardiac valve pathology, despite successful
engraftment after HSCT, is similar to disease progression in
other relatively avascular sites such as bone and joint
(Taylor et al. 2008).
ERT, supplying exogenous human recombinant enzyme by
regular intravenous infusion, is approved for three types of
MPS; laronidasefor MPS I (Wraith et al. 2004), idursulfase for
MPS II (Muenzer et al. 2006) and galsulfase for MPS VI
(Harmatz et al. 2004; Harmatz et al. 2005). Cross-correction
with ERTis achieved in many organs and tissues, reflected by
lower urinary GAG levels and symptomatic improvement.
While galsulfase infusion has been shown to produce
improvement in endurance (walk and stair climb test,
sustained up to 5 years), pulmonary function, joint pain and
stiffness, and growth and organomegaly (Harmatz et al. 2004;
Harmatz et al. 2005; Harmatz et al. 2006; Harmatz et al.
2008), the outcome of ERT is less favorable for poorly
vascularised or “privileged” sites (central nervous system,
cornea, articular cartilage, and cardiac valves).
The effect of ERTalone on cardiac structure and function
in patients with MPS is documented in only a few studies
(Braunlin et al. 2006; Fesslová et al. 2009; Okuyama et al.
2010; Scarpa et al. 2009; Wraith et al. 2007). As with
HSCT, long-term ERT preserves, and may even improve
(Hirth et al. 2007), systolic ventricular function and results
in resolution of ventricular hypertrophy in adults and
children with MPS I and II (Braunlin et al. 2006; Okuyama
et al. 2010; Wraith et al. 2007). However, ERT does not
appear to prevent progression of left-sided cardiac valve
thickening and dysfunction (stenosis, regurgitation) in MPS
I, II and VI. Stabilization of valvular disease in select
patients over a limited study period has been observed
(Braunlin et al. 2006; Fesslová et al. 2009; Okuyama et al.
2010; Scarpa et al. 2009). ERT has been used as an adjunct
in MPS I to lower the GAG burden prior to HSCT (Tolar
and Orchard 2008) and, recently, galsulfase has been found
Operative procedure
performed
Type MPS (patient age
in years/gender)
References
Mitral valve replacement I-S (41 F) (Kitabayashi et al. 2007)
I-H (16 F) (Kraiem et al. 2001)
II (33 M) (Antoniou et al. 2009)
VI (25 F) (Marwick et al. 1992)
Mitral valvuloplasty III (6 F) (Muenzer et al. 1993)
Aortic valve replacement I-S (62 M) (Masuda et al. 1993)
IV (31 F; 41 M) (Nicolini et al. 2008; Pagel and
Almassi 2009)
VI (43 M) (Wilson et al. 1980)
Ross procedure* IV (32 F) (Barry et al. 2006)
Aortic and mitral valve
replacement
I (12 M) (Goksel et al. 2009)
I-S (23-35 M; 42 F; 52 M) (Butman et al. 1989; Fischer et al. 1999;
Minakata et al. 1998)
II (18 M) (Joly et al. 2004)
VI (21 F, 30 M, 34 F; 41 M) (Hachida et al. 1996; Tan et al. 1992)
Coronary artery bypass I-S (56 M) (Minakata et al. 1998)
V entricular septal defect
closure
III (15 M) (Kourouklis et al. 2007)
Coarctectomy I-H (3 M) (Braunlin et al. 2000)
Table 2 Successful cardiac
operative procedures in MPS
disorders
F: female; I-H: Hurler syndrome;
I-S: Scheie syndrome; M: male
*aortic valve replacement by
autologous pulmonary valve
graft
J Inherit Metab Dis (2011) 34:1183–1197 1191to normalize mild elevations in GAG levels found in a
single fully-engrafted patient with MPS VI 20 years after
successful HSCT (Whitley and Utz 2010). Whether these
protocols will have beneficial cardiac effects remains
unstudied.
In contrast to the young age at which most individuals with
MPS undergo HSCT, ERT is usually begun in the older child
(often after 5 years of age) with established cardiac valvular
disease. It is possible that earlier use of ERT may prevent or
amelioratecardiacvalvethickeninganddysfunctioninMPSas
has been shown by two recent sibling studies (Gabrielli et al.
2010; McGill et al. 2010)( T a b l e3). Each older sibling with
either MPS I or MPS VI shared the same enzyme mutation as
his younger sibling and differed only in the age at diagnosis.
The older sibling in each instance, starting with ERT at 4 or
5 years of age, retained the classic phenotypical appearance
of MPS as well as thickening, regurgitation or dysplasia of
the mitral valve (Table 3). By contrast, each younger sibling,
treated with ERT from 8 weeks and 5 months of age and
onwards, respectively, appeared phenotypically normal and
had virtually no cardiac pathology by echocardiography
either before, or after, ERT (Table 3). These data underscore
the importance of newborn or early screening for MPS as
there appears to be a window in early infancy when ERT may
prevent many of the end-organ manifestations of MPS.
Future perspectives
A major step forward in the diagnosis and care of patients
with MPS would be the development, implementation, and
roll-out of a multi-tier screening procedure in newborns.
This screening will identify pre-symptomatic newborns,
allowing for early treatment and prevention or limitation of
morbidity (Marsden and Levy 2010). Continued efforts are
being made to develop easy, reliable and specific blood and
urinary tests for MPS detection based on enzyme activity,
enzyme levels or GAG levels. After validation, it would be
ideal if the existing newborn screening programme will be
expanded to include MPS in addition to other lysosomal
storage disorders.
Additionally, improvements in the choice of donor cells
for HSCT may improve long-term results and result in
lower procedure-induced mortality. In as much as cartilage
and heart valves are both of mesenchymal origin, use of
mesenchymal cells in conjunction with, or after, HSCT may
provide potential to correct tissues currently unresponsive
to either HSCTor cord blood transplantation alone (Boelens
2006). A small number of patients with rapidly progressing
MPS I have received mesenchymal cells in addition to
HSCT (Koç et al. 2002), but results were inconclusive and
further research was recommended.
Finally, results with genetically modified viral vectors have
shown prevention of cardiac valve pathology in dogs with
MPSI orVII (Ponder etal.2002; Sleeper et al. 2004; Traas et
al. 2007), in mice with MPS I that have very high serum
enzyme after neonatal injection of a retroviral vector (Liu et
al. 2005), and in a mouse that received HSCT-directed gene
therapy (Jordan et al. 2005). The use of gene therapy,
including autologous cells treated with viral vectors and then
auto-transfused, remains untested in humans with MPS.
Concluding remarks
Progress in our understanding of MPS has increased
significantly since Hunter and Hurler first reported their
findings. Early case reports were methodically compiled
and systematized by Victor McKusick into the classification
scheme that has served us now for nearly 50 years
Study details Sibling (gender) Echocardiographic abnormalities
At start of ERT (age) Post-ERT (age)
MPS I Hurler-Scheie (Gabrielli
et al. 2010) 5 years ERTat
100 U/kg body weight weekly
Sib 1 (male) None (5 months) None (5 years
and 5 months)
Sib 2 (female) Moderate MR with
thickened valve
leaflets and anterior
edge prolapsed; mild
LA thickening (5 years)
Stabilized cardiac
function without
improvement
(10 years)
MPS VI (McGill et al. 2010)
3.5 years ERTat 1 mg/kg
body weight weekly
Sib 1 (male) None (8 weeks) None (3.6 years)
Sib 2 (female) Mild dysplastic mitral
valve with trivial
MR (3.6 years)
Mild dysplastic
mitral valve with
trivial MR; mild
AR (7.1 years)
Table 3 Impact of early
initiation of enzyme replacement
therapy (ERT) on the course
of MPS according to open-
label, case-control studies
in sibling (sib) pairs
AR: aortic regurgitation; LA: left
atrial; MR: mitral regurgitation
1192 J Inherit Metab Dis (2011) 34:1183–1197(McKusick 1956; McKusick et al. 1965). Based upon the
biochemistry of the disorders, the cardiac pathology and
clinical findings of individual MPS disorders were then
reported (Brosius and Roberts 1981; Krovetz et al. 1965;
Renteria et al. 1976). Successful HSCTwas a pivotal event
in the history of the MPS disorders (Hobbs et al. 1981;
Krivit et al. 1984), providing long-term survival to children
with a previously lethal disease, even though it was soon
apparent that HSCT corrected some but not all disease
features (Taylor et al. 2008). The advent of two-dimensional
echocardiography, occurring soon after successful HSCT,
not only provided the basis for our understanding of the
cardiac abnormalities (Dangel 1998; Gross et al. 1988;
Wippermann et al. 1995), but also became central in the
evaluation of cardiac status before and after treatment. The
development of ERT for MPS I, II and VI has significantly
increased the number of individuals who can receive
treatment for MPS including patients in whom HSCT may
be either unavailable or inappropriate. Ongoing registries or
surveillance programmes in MPS I, II, IV A and VI are
beginning to provide large-scale international data on the
scope and progression of various disease manifestations
(Montañoetal.2007; Pastores et al. 2007; Wraith et al. 2008;
http://www.naglazyme.com/en/Clinical-resources/surveil
lance-program.aspx - retrieved from 15 April 2011; http://
clinicaltrials.gov/ct2/show/NCT00214773?term=NC
T00214773&rank=1 - retrieved from 15 April 2011) and
may, in the future, serve as a mechanism for the evaluation of
novel therapies.
Much remains to be learned about the heart and great
vessels in MPS both before and after treatment. The natural
history, cardiac findings, and pathology of all of the MPS
(sub)types remains incomplete; defining specific MPS
mutations associated with more severe cardiac pathology
will improve and refine patient care. The development of
neonatal screening for MPS will generate a need for
answers to these and other questions.
Finally, because GAGs are an integral part of the cardiac
valve and vasculature of normal hearts, the MPS disorders
provide exquisite ‘experiments of nature’ that may yield
insight into arenas as diverse as the development of
autologous bioengineered cardiac valves (Sacks et al. 2009)
and the pathobiology of atherosclerotic cardiovascular
disease (Nakashima et al. 2008).
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